We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Chest Physiotherapy in Hyperventilation Syndrome (SHV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05488301
Recruitment Status : Recruiting
First Posted : August 4, 2022
Last Update Posted : August 4, 2022
Sponsor:
Information provided by (Responsible Party):
Marc Beaumont, Centre Hospitalier des Pays de Morlaix

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Hyperventilation syndrome induce dyspnea and altered quality of life. the aim of this study is to assess the impact of chest physiotherapy on hyperventilation syndrome' symptoms

Condition or disease Intervention/treatment
Hyperventilation Other: chest physiotherapy

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 45 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 3 Months
Official Title: Effects of Chest Physiotherapy in Hyperventilation Syndrom : a Multicentric Observational Study
Actual Study Start Date : October 1, 2021
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2023
Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Other: chest physiotherapy

    chest physiotherapy session including:

    • nasal ventilation
    • decrease of respiratory rate without increasement of Tidal volume
    • abdomino-diaphragmatic ventilation

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. change of Nijmegen score [ Time Frame: 5 weeks ]
    Nijmegen score is measured at baseline and after 5 weeks. The Nijmegen questionnaire allows to assess hyperventilation symptoms. the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.


Secondary Outcome Measures :
  1. change of Nijmegen Score [ Time Frame: 1 week ]
    Nijemegen score is measured at baseline and after 1 week. The Nijmegen questionnaire allows to assess hyperventilation symptoms the minimum and maximum values are between 0 to 64, and higher scores mean a worse outcome.

  2. change of Hospital Anxiety and Depression score (HAD) [ Time Frame: 5 weeks ]
    Anxiety and depression scores are measured at baseline and after 5 weeks. the minimum and maximum values are between 0 to 21 for each item (Anxiety and Depression), and higher scores mean a worse outcome.

  3. change of Short Form-36 score (SF-36) [ Time Frame: 5 weeks ]

    SF 36 score is measured at baseline and after 5 weeks. SF36 allows to assess quality of life.

    the minimum and maximum values are between 0 to 100, and higher scores mean a better outcome.


  4. change of Dyspnea-12 score [ Time Frame: 5 weeks ]

    Dyspnea-12 is measured at at baseline and after 5 weeks.

    Dyspnea-12 questionnaire allows to assess sensorial and emotional component of dyspnea. The minimum and maximum values are between à to 36, and higher scores mean a worse outcome.



Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients with hyperventilation syndrome adressed for chest physiotherapy
Criteria

Inclusion Criteria:

  • patients addressed for hyperventilation syndrome
  • patient aged 18 years or over
  • patient able to consent and having sign a consent form

Exclusion Criteria:

  • respiratory disease (COPD, interstitial lung disease, bronchiectasis, cystic fibrosis, uncontrolled asthma)
  • patient with an inability to complete questionaires
  • refusal of participation
  • patient under tutorship or curatorship
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05488301


Locations
Layout table for location information
France
BEAUMONT Recruiting
Morlaix, France, 29600
Contact: MARC BEAUMONT, PhD    0298626160 ext 7750    mbeaumont@ch-morlaix.fr   
Contact: MARC BEAUMONT, PhD       marc.beaumont@univ-brest.fr   
Sponsors and Collaborators
Centre Hospitalier des Pays de Morlaix
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Marc Beaumont, Principal Investigator, Centre Hospitalier des Pays de Morlaix
ClinicalTrials.gov Identifier: NCT05488301    
Other Study ID Numbers: CHPMorlaix
CEPRO 2021-028 ( Registry Identifier: SPLF )
First Posted: August 4, 2022    Key Record Dates
Last Update Posted: August 4, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Marc Beaumont, Centre Hospitalier des Pays de Morlaix:
hyperventilation
quality of life
dyspnea
Nijmegen
anxiety
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperventilation
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory